Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 152

1.

Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men.

Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Sykes J, Lockwood G, van der Kwast TH.

J Natl Cancer Inst. 2013 Jul 17;105(14):1050-8. doi: 10.1093/jnci/djt151. Epub 2013 Jul 11.

2.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

3.

Prostate cancer mortality in the Finnish randomized screening trial.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

J Natl Cancer Inst. 2013 May 15;105(10):719-25. doi: 10.1093/jnci/djt038. Epub 2013 Mar 11.

4.

Risk of suicide in men with low-risk prostate cancer.

Carlsson S, Sandin F, Fall K, Lambe M, Adolfsson J, Stattin P, Bill-Axelson A.

Eur J Cancer. 2013 May;49(7):1588-99. doi: 10.1016/j.ejca.2012.12.018. Epub 2013 Jan 19.

PMID:
23337463
5.

Quality-of-life effects of prostate-specific antigen screening.

Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ.

N Engl J Med. 2012 Aug 16;367(7):595-605. doi: 10.1056/NEJMoa1201637.

6.

Radical prostatectomy versus observation for localized prostate cancer.

Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group.

N Engl J Med. 2012 Jul 19;367(3):203-13. doi: 10.1056/NEJMoa1113162. Erratum in: N Engl J Med. 2012 Aug 9;367(6):582.

7.

Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial.

Taylor KL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, Davis KM, Dawson DL, Edmond S, Reding D, Mabie JE, Riley TL.

J Clin Oncol. 2012 Aug 1;30(22):2768-75. doi: 10.1200/JCO.2011.41.2767. Epub 2012 Jun 25.

8.

The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines.

Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB.

Cancer. 2012 Dec 1;118(23):5955-63. doi: 10.1002/cncr.27594. Epub 2012 May 17.

9.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

10.

Randomised prostate cancer screening trial: 20 year follow-up.

Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P.

BMJ. 2011 Mar 31;342:d1539. doi: 10.1136/bmj.d1539.

11.

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H.

Lancet Oncol. 2010 Aug;11(8):725-32. doi: 10.1016/S1470-2045(10)70146-7. Epub 2010 Jul 2.

12.

Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.

Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden.

J Natl Cancer Inst. 2010 Jul 7;102(13):950-8. doi: 10.1093/jnci/djq154. Epub 2010 Jun 18.

13.

Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States.

Fang F, Keating NL, Mucci LA, Adami HO, Stampfer MJ, Valdimarsdóttir U, Fall K.

J Natl Cancer Inst. 2010 Mar 3;102(5):307-14. doi: 10.1093/jnci/djp537. Epub 2010 Feb 2.

14.

Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study.

Fall K, Fang F, Mucci LA, Ye W, Andrén O, Johansson JE, Andersson SO, Sparén P, Klein G, Stampfer M, Adami HO, Valdimarsdóttir U.

PLoS Med. 2009 Dec;6(12):e1000197. doi: 10.1371/journal.pmed.1000197. Epub 2009 Dec 15.

15.

Screening and prostate-cancer mortality in a randomized European study.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators.

N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.

16.

Mortality results from a randomized prostate-cancer screening trial.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18. Erratum in: N Engl J Med. 2009 Apr 23;360(17):1797.

17.

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.

Grubb RL 3rd, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabie JE, Levin DL, Chia D, Kramer BS, Reding DJ, Church TR, Yokochi LA, Kvale PA, Weissfeld JL, Urban DA, Buys SS, Gelmann EP, Ragard LR, Crawford ED, Prorok PC, Gohagan JK, Berg CD, Andriole GL.

BJU Int. 2008 Dec;102(11):1524-30. doi: 10.1111/j.1464-410X.2008.08214.x.

18.

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, Björk T, Berglund G, Vickers AJ, Lilja H.

J Clin Oncol. 2008 Feb 20;26(6):835-41. doi: 10.1200/JCO.2007.13.1490.

19.
20.

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.

Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA Jr.

J Urol. 2007 May;177(5):1749-52.

PMID:
17437804
Items per page

Supplemental Content

Write to the Help Desk